SeaStar Medical announces newly published QUELIMMUNE therapy

SeaStar Medical (ICU) announced the publication of a health economic analysis estimating significant cost savings with the use of the QUELIMMUNE therapy in pediatric patients with Acute Kidney Injury in the ICU setting. The analysis, as presented in the Journal of Medical Economics estimates a cost savings of $69,146 per hospitalization when the QUELIMMUNE therapy is administered compared to modeled hospitalization costs with standard continuous renal replacement therapy. These projected savings are estimated to offset the cost of the QUELIMMUNE therapy with a potential for institutions to incur no out-of-pocket costs for 6 days of treatment of pediatric AKI. “Data from the QUELIMMUNE clinical studies showed organ sparing and life-saving benefits for critically ill pediatric patients with AKI requiring CRRT,” stated Kevin Chung, MD, Chief Medical Officer of SeaStar Medical and co-author of the publication. “Our analysis shows that the QUELIMMUNE therapy may “pay for itself” with the projected savings.”